Developer docs
API playgroundTry for free, no card

Search company profiles

Molecular Devices

Full company profile

uuid0005m68

Namestring
Molecular Devices
Legal namestring
Molecular Devices, LLC
Company typeenum
Private
Founded yearint
1983
Descriptiontext

Molecular Devices, LLC is a life science instrumentation company operating as a wholly-owned subsidiary of Danaher Corporation within its Life Sciences segment. The company designs and manufactures bioanalytical measurement systems—including SpectraMax iD3s/iD5e multi-mode microplate readers, ImageXpress HCS.ai high-content screening systems, CellXpress.ai automated cell culture platforms, QPix FLEX microbial colony pickers, ClonePix mammalian colony pickers, and the ImageXpress Confocal HT.ai imaging system—used by pharmaceutical, biotechnology, academic core lab, contract research organization, and GxP-regulated laboratory customers for drug discovery, cell line development, toxicity assessment, and 3D biology research.

The company's underlying technology combines precision optical and liquid-handling hardware with an AI-driven software stack (IN Carta with SINAP deep learning segmentation and Phenoglyphs ML classification, MetaXpress acquisition/analysis software, SoftMax Pro control and GxP-compliance software) and consumable services, notably the 3D Ready Organoid Expansion Service built on proprietary bioreactor technology acquired through the December 2022 Cellesce acquisition. Underlying technical components include a Deep Tissue Confocal Spinning Disk module delivering a 4.5-fold signal-to-noise improvement for thick 3D samples, standardized automated workcells integrating Precise Automation PreciseFlex robots, Biosero Green Button Go scheduling, LiCONiC Wave STX44 incubators, Bionex HiG4 centrifuges, Beckman Coulter Biomek i7 liquid handlers, and AquaMax plate washers. Revenue derives from a mix of capital equipment sales (hardware), recurring software licensing and maintenance (SoftMax Pro, IN Carta, MetaXpress), organoid and consumable products and services (3D Ready expansion and standard PDOs), professional services (IQ/OQ/PM validation), and licensed biomarker workflow integration (Abcam co-development). Go-to-market relies on direct enterprise field sales staffed with application scientists, quote-based consultative pricing, conference presence (SLAS, ISSCR, synthetic biology events), and integration partnerships with the Automata LINQ lab automation platform and Beckman Coulter Life Sciences within the broader Danaher ecosystem.

Short descriptiontext

Molecular Devices is a Danaher subsidiary that designs and sells bioanalytical instruments—including SpectraMax microplate readers, AI-powered high-content screening systems, automated cell culture platforms, and 3D organoid services—to pharmaceutical, biotechnology, academic, and CRO customers for drug discovery and complex biology research.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersSunnyvale, United States
HQ citystring
Sunnyvale
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life science instrumentation, microplate readers, high content imaging, lab automation systems, cell culture instruments
Industry2 codes
1Microscopy, Imaging & Flow Cytometry Instruments
CodeHLAGAIAEPrimaryYes
2AI/ML Platforms for Drug Discovery & Experiment Optimization
CodeHLAGAJAOPrimaryNo
NAICS code1 code
  • Analytical Laboratory Instrument Manufacturing334516
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Life Science Instrumentation
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1Laboratory Instruments and Hardware
TypeHardware Sales
Description

Sale of high-value laboratory instruments including microplate readers, high-content screening systems, automated cell culture systems, colony picking systems, and associated hardware. These are capital equipment purchases with typically multi-year lifecycles.

moleculardevices.com
2Software Licenses and Subscriptions
TypeSubscription Recurring
Description

Software products including IN Carta image analysis software, SoftMax Pro data analysis software, and MetaXpress HCI software. May include licensing fees and maintenance subscriptions.

moleculardevices.com
3Organoid Products and Services
TypeOne Time License
Description

3D Ready Organoid Expansion Service providing standardized, assay-ready organoids for drug discovery and research applications. Includes custom organoid production and expansion services.

moleculardevices.com
4Service and Support
TypeProfessional Services
Description

IQ/OQ/PM validation services, technical support, and laboratory automation solutions integration services for GMP/GLP compliant labs.

moleculardevices.com
5Integrated Workflow Solutions
TypeLicensing Royalties
Description

Partnership with Abcam for integrated biomarker discovery workflows combining validated assay kits, automation-ready microplate readers, and integrated data analysis software.

moleculardevices.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 10 records shown
13D Ready™
Description

Organoid expansion service brand for scalable and consistent patient-derived organoids

moleculardevices.com
+9 more records
Core offering1 text field

Molecular Devices designs, manufactures, and sells high-performance bioanalytical measurement instruments, software, and automation systems used in life science research and drug discovery. Its portfolio spans microplate readers, high-content imaging systems, colony pickers, patch-clamp electrophysiology platforms, and automated cell culture systems, complemented by AI-powered image analysis and data acquisition software for pharmaceutical, biotechnology, and academic research customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 4.5-fold improvement in signal-to-noise ratio for 3D organoid imaging
+4 more records
Product overview1 text field

Molecular Devices is a life science instrumentation company offering a comprehensive portfolio of products for cellular analysis, drug discovery, and 3D biology research. The portfolio centers on SpectraMax microplate readers and SoftMax Pro GxP software for bioanalytical measurement; ImageXpress HCS.ai high-content screening systems with IN Carta AI-powered image analysis software for cellular imaging; CellXpress.ai automated cell culture system for 3D organoid workflows; QPix FLEX microbial colony picking and clone screening systems for cell line development; and the 3D Ready Organoid Expansion Service for scalable patient-derived organoid production. These products integrate through lab automation solutions including automated workcells combining instruments from Precise Automation, Biosero, Beckman Coulter Biomek, and LiCONiC, all connected via scheduling software. The company, a Danaher Corporation subsidiary, also offers GxP compliance solutions for regulated laboratories and operates an Organoid Innovation Center for collaborative research.

Product and service10 records
1CellXpress.ai Automated Cell Culture System
CategoryCell Culture Automation
Description

An AI-driven, GMP-ready automated cell culture system with integrated incubator, liquid handling, and on-deck imaging/analytics for cell line maintenance and expansion in biopharma.

2IN Carta Image Analysis Software
CategoryImage Analysis Software
Description

Deep learning–based image analysis software for high-content screening, enabling phenotype classification, 3D organoid analysis, and AI-assisted data interpretation.

33D Ready Organoid Services
CategoryContract Research Services
Description

Fee-for-service offering that cultures, screens, and analyzes patient-derived organoids for preclinical drug discovery and translational research customers.

4QPix Colony Picker Systems
CategoryLab Automation
Description

Automated microbial colony pickers that identify, pick, and re-array bacterial or yeast colonies at industrial throughput for synthetic biology and strain engineering.

5ImageXpress Confocal Microscopy System
CategoryHigh-Content Imaging
Description

High-content confocal imaging system for 3D, live-cell, and phenotypic screening assays in drug discovery and cell biology research.

6SpectraMax Microplate Readers
CategoryMicroplate Detection
Description

Multimode microplate readers for absorbance, fluorescence, luminescence, and other optical detection in biochemical and cell-based assays.

7FLIPR Penta System
CategoryCellular Screening
Description

High-throughput kinetic cell-based screening system used to measure calcium flux and other rapid fluorescence responses in GPCR and ion channel drug discovery.

8Axon Patch-Clamp Systems
CategoryElectrophysiology
Description

Manual and automated patch-clamp electrophysiology instruments and consumables for ion channel research and cardiac safety screening.

9MetaXpress High-Content Image Analysis Software
CategoryImage Analysis Software
Description

Image acquisition and analysis software that controls high-content screening instruments and quantifies phenotypic data.

10SoftMax Pro Software
CategoryData Analysis Software
Description

Data acquisition and analysis software for SpectraMax and other microplate readers, providing protocol control, curve fitting, and compliance-ready reporting.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-02-10
Description

Both Molecular Devices and Beckman Coulter Life Sciences (Danaher operating companies) are integrating their instruments with Automata's LINQ platform to create a unified ecosystem across multiple Danaher life sciences brands, eliminating manual bottlenecks in research workflows.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-29
Description

Molecular Devices partnered with London-based Automata to integrate its automated imaging and detection systems with Automata's LINQ platform, enabling connected, scalable, AI-ready research workflows. Danaher Ventures participated in Automata's Series C funding round and secured a board appointment. The collaboration also incorporates Beckman Coulter Life Sciences instruments, aiming to help scientific teams boost throughput and data quality while managing limited hands-on resources without added operational complexity.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-10
Description

Partnership to provide integrated biomarker discovery workflows combining validated assay kits, automation-ready microplate readers, and integrated data analysis software. Collaboration tested in human ALT liver toxicity study demonstrating 4X more data with 60% less hands-on time compared to traditional approaches.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-04-01
Description

Acquisition expanded portfolio to include mobile CT, MRI, and PET scanners for rentals, complementing the existing imaging and detection product lines.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-12-06
Description

Acquisition of Cardiff-based Cellesce specializing in large-scale production of patient-derived organoids (PDOs). Deal enabled creation of consistent human-derived organoids for high-throughput drug screening, potentially reducing drug development timelines. Cellesce's organoid production capabilities and expertise integrated into Molecular Devices' 3D Ready portfolio.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration13 records

Each record includes

Title, Type, Description, Source

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Molecular Devices

Life Science Instrumentationmoleculardevices.com

Molecular Devices is a Danaher subsidiary that designs and sells bioanalytical instruments—including SpectraMax microplate readers, AI-powered high-content screening systems, automated cell culture platforms, and 3D organoid services—to pharmaceutical, biotechnology, academic, and CRO customers for drug discovery and complex biology research.

What Molecular Devices does

Molecular Devices, LLC is a life science instrumentation company operating as a wholly-owned subsidiary of Danaher Corporation within its Life Sciences segment. The company designs and manufactures bioanalytical measurement systems—including SpectraMax iD3s/iD5e multi-mode microplate readers, ImageXpress HCS.ai high-content screening systems, CellXpress.ai automated cell culture platforms, QPix FLEX microbial colony pickers, ClonePix mammalian colony pickers, and the ImageXpress Confocal HT.ai imaging system—used by pharmaceutical, biotechnology, academic core lab, contract research organization, and GxP-regulated laboratory customers for drug discovery, cell line development, toxicity assessment, and 3D biology research.

The company's underlying technology combines precision optical and liquid-handling hardware with an AI-driven software stack (IN Carta with SINAP deep learning segmentation and Phenoglyphs ML classification, MetaXpress acquisition/analysis software, SoftMax Pro control and GxP-compliance software) and consumable services, notably the 3D Ready Organoid Expansion Service built on proprietary bioreactor technology acquired through the December 2022 Cellesce acquisition. Underlying technical components include a Deep Tissue Confocal Spinning Disk module delivering a 4.5-fold signal-to-noise improvement for thick 3D samples, standardized automated workcells integrating Precise Automation PreciseFlex robots, Biosero Green Button Go scheduling, LiCONiC Wave STX44 incubators, Bionex HiG4 centrifuges, Beckman Coulter Biomek i7 liquid handlers, and AquaMax plate washers. Revenue derives from a mix of capital equipment sales (hardware), recurring software licensing and maintenance (SoftMax Pro, IN Carta, MetaXpress), organoid and consumable products and services (3D Ready expansion and standard PDOs), professional services (IQ/OQ/PM validation), and licensed biomarker workflow integration (Abcam co-development). Go-to-market relies on direct enterprise field sales staffed with application scientists, quote-based consultative pricing, conference presence (SLAS, ISSCR, synthetic biology events), and integration partnerships with the Automata LINQ lab automation platform and Beckman Coulter Life Sciences within the broader Danaher ecosystem.

Molecular Devices firmographics

Firmographics
Name
Molecular Devices
Legal name
Molecular Devices, LLC
Website
https://moleculardevices.com
Company type
Private
Founded year
1983
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Molecular Devices is a Danaher subsidiary that designs and sells bioanalytical instruments—including SpectraMax microplate readers, AI-powered high-content screening systems, automated cell culture platforms, and 3D organoid services—to pharmaceutical, biotechnology, academic, and CRO customers for drug discovery and complex biology research.
Ownership category
akta.pro rank

Molecular Devices industry classification

Industry
Product category
Life Science Instrumentation
NAICS
Analytical Laboratory Instrument Manufacturing (334516)
SIC
Laboratory Analytical Instruments (3826)
akta.pro primary industry
Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)
akta.pro secondary industry
AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

  • Life science instrumentation
  • Microplate readers
  • High content imaging
  • Lab automation systems
  • Cell culture instruments

Where Molecular Devices is headquartered

Location

Headquarters

HQ city
Sunnyvale
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Molecular Devices business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Laboratory Instruments and Hardware: Sale of high-value laboratory instruments including microplate readers, high-content screening systems, automated cell culture systems, colony picking systems, and associated hardware. These are capital equipment purchases with typically multi-year lifecycles.
  2. Software Licenses and Subscriptions: Software products including IN Carta image analysis software, SoftMax Pro data analysis software, and MetaXpress HCI software. May include licensing fees and maintenance subscriptions.
  3. Organoid Products and Services: 3D Ready Organoid Expansion Service providing standardized, assay-ready organoids for drug discovery and research applications. Includes custom organoid production and expansion services.
  4. Service and Support: IQ/OQ/PM validation services, technical support, and laboratory automation solutions integration services for GMP/GLP compliant labs.
  5. Integrated Workflow Solutions: Partnership with Abcam for integrated biomarker discovery workflows combining validated assay kits, automation-ready microplate readers, and integrated data analysis software.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Molecular Devices product offering

Product offering

Core offering

Molecular Devices designs, manufactures, and sells high-performance bioanalytical measurement instruments, software, and automation systems used in life science research and drug discovery. Its portfolio spans microplate readers, high-content imaging systems, colony pickers, patch-clamp electrophysiology platforms, and automated cell culture systems, complemented by AI-powered image analysis and data acquisition software for pharmaceutical, biotechnology, and academic research customers.

Product overview

Molecular Devices is a life science instrumentation company offering a comprehensive portfolio of products for cellular analysis, drug discovery, and 3D biology research. The portfolio centers on SpectraMax microplate readers and SoftMax Pro GxP software for bioanalytical measurement; ImageXpress HCS.ai high-content screening systems with IN Carta AI-powered image analysis software for cellular imaging; CellXpress.ai automated cell culture system for 3D organoid workflows; QPix FLEX microbial colony picking and clone screening systems for cell line development; and the 3D Ready Organoid Expansion Service for scalable patient-derived organoid production. These products integrate through lab automation solutions including automated workcells combining instruments from Precise Automation, Biosero, Beckman Coulter Biomek, and LiCONiC, all connected via scheduling software. The company, a Danaher Corporation subsidiary, also offers GxP compliance solutions for regulated laboratories and operates an Organoid Innovation Center for collaborative research.

Differentiator

Problem solved

Functional benefit

Brands

  • 3D Ready™: Organoid expansion service brand for scalable and consistent patient-derived organoids
  • SpectraMax®
  • ImageXpress®
  • CellXpress.ai®
  • QPix®
  • ClonePix®
  • CloneSelect®
  • DispenCell™
  • IN Carta®
  • SoftMax® Pro

Products and services

  • CellXpress.ai Automated Cell Culture System An AI-driven, GMP-ready automated cell culture system with integrated incubator, liquid handling, and on-deck imaging/analytics for cell line maintenance and expansion in biopharma.
  • IN Carta Image Analysis Software Deep learning–based image analysis software for high-content screening, enabling phenotype classification, 3D organoid analysis, and AI-assisted data interpretation.
  • 3D Ready Organoid Services Fee-for-service offering that cultures, screens, and analyzes patient-derived organoids for preclinical drug discovery and translational research customers.
  • QPix Colony Picker Systems Automated microbial colony pickers that identify, pick, and re-array bacterial or yeast colonies at industrial throughput for synthetic biology and strain engineering.
  • ImageXpress Confocal Microscopy System High-content confocal imaging system for 3D, live-cell, and phenotypic screening assays in drug discovery and cell biology research.
  • SpectraMax Microplate Readers Multimode microplate readers for absorbance, fluorescence, luminescence, and other optical detection in biochemical and cell-based assays.
  • FLIPR Penta System High-throughput kinetic cell-based screening system used to measure calcium flux and other rapid fluorescence responses in GPCR and ion channel drug discovery.
  • Axon Patch-Clamp Systems Manual and automated patch-clamp electrophysiology instruments and consumables for ion channel research and cardiac safety screening.
  • MetaXpress High-Content Image Analysis Software Image acquisition and analysis software that controls high-content screening instruments and quantifies phenotypic data.
  • SoftMax Pro Software Data acquisition and analysis software for SpectraMax and other microplate readers, providing protocol control, curve fitting, and compliance-ready reporting.

Quantifiable outcome

  • 4.5-fold improvement in signal-to-noise ratio for 3D organoid imaging
  • +4 more outcomes

Companies that use Molecular Devices

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Molecular Devices technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration13 records

AI capability9 records

Feature10 records

Molecular Devices partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Beckman Coulter Life SciencescoreTechnology or Integration · 10 February 2026Both Molecular Devices and Beckman Coulter Life Sciences (Danaher operating companies) are integrating their instruments with Automata's LINQ platform to create a unified ecosystem across multiple Danaher life sciences brands, eliminating manual bottlenecks in research workflows.
  • AutomatacoreTechnology or Integration · 29 January 2026Molecular Devices partnered with London-based Automata to integrate its automated imaging and detection systems with Automata's LINQ platform, enabling connected, scalable, AI-ready research workflows. Danaher Ventures participated in Automata's Series C funding round and secured a board appointment. The collaboration also incorporates Beckman Coulter Life Sciences instruments, aiming to help scientific teams boost throughput and data quality while managing limited hands-on resources without added operational complexity.
  • AbcamcoreStrategic or Co-development Partner · 10 October 2025Partnership to provide integrated biomarker discovery workflows combining validated assay kits, automation-ready microplate readers, and integrated data analysis software. Collaboration tested in human ALT liver toxicity study demonstrating 4X more data with 60% less hands-on time compared to traditional approaches.
  • Interim Diagnostic ImagingminorOEM/ Whitelabel/ Licensing Partner · 1 April 2023Acquisition expanded portfolio to include mobile CT, MRI, and PET scanners for rentals, complementing the existing imaging and detection product lines.
  • CellescecoreOEM/ Whitelabel/ Licensing Partner · 6 December 2022Acquisition of Cardiff-based Cellesce specializing in large-scale production of patient-derived organoids (PDOs). Deal enabled creation of consistent human-derived organoids for high-throughput drug screening, potentially reducing drug development timelines. Cellesce's organoid production capabilities and expertise integrated into Molecular Devices' 3D Ready portfolio.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Molecular Devices competitors and assessment

Company assessment

Market position

Strengths4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Molecular Devices social profiles

Digital presence

Molecular Devices compliance and trust

Trust signal

Compliance1 record

Molecular Devices financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Molecular Devices leadership team

Management profile

Number of profiles

Profiles5 records

Molecular Devices subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Molecular Devices funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Molecular Devices M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Molecular Devices

What does Molecular Devices do?

Molecular Devices designs, manufactures, and sells high-performance bioanalytical measurement instruments, software, and automation systems used in life science research and drug discovery. Its portfolio spans microplate readers, high-content imaging systems, colony pickers, patch-clamp electrophysiology platforms, and automated cell culture systems, complemented by AI-powered image analysis and data acquisition software for pharmaceutical, biotechnology, and academic research customers.

Is Molecular Devices a public or private company?

Molecular Devices is a private company. It is classified as corporate owned and is currently operating.

When was Molecular Devices founded?

Molecular Devices was founded in 1983. It employs 1,001 to 5,000 people.

Where is Molecular Devices based?

Molecular Devices is headquartered in Sunnyvale, United States, in the North America region.

How does Molecular Devices make money?

Five revenue lines are on record. Laboratory Instruments and Hardware is the primary driver. The others are software Licenses and Subscriptions, organoid Products and Services, service and Support and integrated Workflow Solutions.

Does Molecular Devices have an API?

No public API is recorded for Molecular Devices.

What industry is Molecular Devices in?

Molecular Devices's product category is Life Science Instrumentation. Its primary akta.pro industry code is HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments, with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrwebMolecular Devices Expands SoftMax® Pro GxP Software Suite with GLP Mode to Help Laboratories Advance Confidently from Discovery Toward Regulated ComplianceMolecular Devices introduced SoftMax Pro 7.6 GLP Mode, adding enhanced user management, electronic signatures, and audit-ready reporting to its GxP software suite. The mode helps laboratories strengthen data integrity and workflow oversight as they progress from discovery toward regulated environments. The suite is now available worldwide.PrwebMolecular Devices and STEMCELL Technologies Collaborate to Accelerate Adoption of Human-Relevant Organoid Models Through AutomationMolecular Devices and STEMCELL Technologies announced a validated automated workflow for culturing human intestinal organoids on the CellXpress.ai system, using STEMCELL's IntestiCult Plus medium. The downloadable protocol aims to reduce hands-on time and variability, and is the first milestone in a collaboration to automate STEMCELL's organoid culture kits.News-MedicalAI label-free detection with IN Carta image analysisMolecular Devices developed a label-free AI model in IN Carta software to segment nuclei from transmitted-light images, achieving over 97% accuracy on U2OS cells. The model was validated across five cell lines with over 90% detection accuracy and comparable IC50 values to DAPI-based methods, enabling real-time compound screening.PrwebMolecular Devices and HeartBeat.bio Help Researchers Identify Cardiac Safety Risks Earlier with New Human Cardiac Organoid SolutionMolecular Devices and HeartBeat.bio announced the upcoming availability of the 3D Ready™ Cardioid Supplement Kit, the first commercial product from their collaboration combining cardiac organoid biology with automated cellular workflows for drug discovery and safety assessment. The kit addresses key barriers to cardiac organoid adoption by providing standardized, scalable cardiac models from human induced pluripotent stem cells for toxicity testing. Commercial availability is planned for Fall 2026, with early-access applications now open.Danaher CorporationDanaher Completes Acquisition of AB SCIEX and Molecular DevicesDanaher completed its acquisition of AB SCIEX and Molecular Devices, adding mass spectrometers and bio-analytical instrumentation to its portfolio. The companies serve researchers and clinicians, and Danaher reported $11.2 billion in revenue in 2009.openPR.comGlobal Factors Influencing the Rapid Evolution of the 3D Diagnostic Imaging Services MarketThe 3D diagnostic imaging services market is projected to reach $426.48 billion by 2030, growing at a compound annual growth rate of 8.0%, driven by AI-powered imaging analysis, increased investment in diagnostic technologies, and rising demand for precision diagnostics. In April 2023, Molecular Devices acquired Interim Diagnostic Imaging, expanding its portfolio to include mobile CT, MRI, and PET scanners for rentals. In January 2024, Align Technology Inc. launched the iTero Lumina intraoral scanner featuring a 3X wider field of capture in a smaller device.News-MedicalAchieving automated and robust brain organoid generationMolecular Devices has developed the CellXpress.ai Automated Cell Culture System, which integrates liquid handling, imaging, and incubation capabilities to automate brain organoid generation from induced pluripotent stem cells. The system addresses key challenges in organoid production including low reproducibility, high variability between samples, and labor-intensive manual processes that impede scalability in drug discovery and disease modeling applications. Researchers used the platform to demonstrate an automated workflow incorporating rocking incubators and AI-assisted image analysis to improve consistency and reduce hands-on time for brain organoid culture.Market ScoopAI in MicroscopyThe Global AI in Microscopy Market is projected to grow from US$ 1.5 billion in 2025 to US$ 6.3 billion by 2035, representing a compound annual growth rate of 15.4%, with North America capturing over 53% market share in 2025. Hospital laboratories represent the dominant end-use segment at 48.5%, while image restoration applications lead the application segment with 34.2% market share, driven by increasing demand for high-throughput, high-accuracy imaging in life sciences and materials research. Key players including Thermo Fisher Scientific, ZEISS, Leica Microsystems, Nikon, and Molecular Devices have launched new AI-integrated microscopy platforms in 2025, with FDA 510(k) clearance granted for AI-assisted pathology slide analysis systems, accelerating integration of AI tools into clinical microscopy practice.Technology NetworksAI-Enabled Imaging Solutions for Complex 3D Organoid ScreeningMolecular Devices published an application note demonstrating the capabilities of its ImageXpress HCS.ai High-Content Screening System combined with IN Carta image analysis software for imaging and analyzing 3D patient-derived colorectal cancer organoids in drug discovery workflows. The case study showed that the Deep Tissue Confocal Spinning Disk module achieved a 4.5-fold improvement in signal-to-noise ratio compared to standard disk configurations when imaging through thick 3D samples. Using AI-powered segmentation (SINAP) and classification tools (Phenoglyphs), researchers successfully quantified dose-dependent phenotypic responses, including a calculated EC50 of 128 μM for 5-fluorouracil, enabling more accurate drug efficacy and toxicity testing using physiologically relevant organoid models.RdworldonlineMolecular Devices and Automata partner to connect lab instrumentsMolecular Devices, a Danaher Corporation company, has announced a strategic collaboration with London-based Automata to integrate its imaging systems and microplate readers with Automata's LINQ platform, enabling lab instruments from different brands to communicate and move samples via software and robotics without human intervention. Danaher Ventures participated in Automata's Series C funding round and secured a board seat as part of the deal, while Beckman Coulter Life Sciences, another Danaher company, is also integrating its instruments with the LINQ platform to create a unified ecosystem across multiple Danaher life sciences brands. The collaboration aims to eliminate manual bottlenecks in research workflows that introduce variability and potential error when scientists manually move plates between instruments.